BCG Vaccine Related Published Studies
Well-designed clinical trials related to BCG Vaccine (Bacillus Calmette-Guerin)
Randomized trial of BCG vaccination at birth to low-birth-weight children: beneficial nonspecific effects in the neonatal period? [2011.07.15]
Evidence of an effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: second report of the BCG-REVAC cluster-randomised trial. [2011.07.12]
Maintenance therapy with bacillus Calmette-Guerin Connaught strain clearly prolongs recurrence-free survival following transurethral resection of bladder tumour for non-muscle-invasive bladder cancer. [2011.07]
NRAMP1 and hGPX1 gene polymorphism and response to bacillus Calmette-Guerin therapy for bladder cancer. [2011.03]
Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guerin and with bacillus Calmette-Guerin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTC genito-urinary group randomized phase 2 trial (30993). [2011.03]
BCG vaccination and allergy: a systematic review and meta-analysis. [2011.01]
Neonatal BCG vaccination induces IL-10 production by CD4+ CD25+ T cells. [2010.11]
Bacillus Calmette-Guerin with or without interferon alpha-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer. [2010.11]
[Prevention of topic toxicity of BCG with single-dose prulifloxacin. Preliminary results of a randomized pilot study]. [2010.10]
Maintenance intravesical bacillus Calmette-Guerin instillation for Ta, T1 cancer and carcinoma in situ of the bladder: randomized controlled trial by the BCG Tokyo Strain Study Group. [2010.09]
Delaying bacillus Calmette-Guerin vaccination from birth to 4 1/2 months of age reduces postvaccination Th1 and IL-17 responses but leads to comparable mycobacterial responses at 9 months of age. [2010.08.15]
Oral polio vaccine influences the immune response to BCG vaccination. A natural experiment. [2010.05.21]
Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guerin, and bacillus Calmette-Guerin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. [2010.05]
Effect of revaccination with BCG in early childhood on mortality: randomised trial in Guinea-Bissau. [2010.03.15]
Vitamin A supplementation and BCG vaccination at birth in low birthweight neonates: two by two factorial randomised controlled trial. [2010.03.09]
Field evaluation of the protective efficacy of Mycobacterium bovis BCG vaccine against bovine tuberculosis. [2010.02]
Bacillus Calmette-Guerin is superior to a combination of epirubicin and interferon-alpha2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study. [2010.01]
Bacillus Calmette-Guerin versus gemcitabine for intravesical therapy in high-risk superficial bladder cancer: a randomised prospective study. [2010]
Protective effect of the combination BCG vaccination and rifampicin prophylaxis in leprosy prevention. [2009.11.23]
Delaying BCG vaccination from birth to 10 weeks of age may result in an enhanced memory CD4 T cell response. [2009.09.04]
Short-term administration of prulifloxacin in patients with nonmuscle-invasive bladder cancer: an effective option for the prevention of bacillus Calmette-Guerin-induced toxicity? [2009.09]
Predictive value of urinary interleukin-8 cutoff point for recurrences after transurethral resection plus induction bacillus Calmette-Guerin treatment in non-muscle-invasive bladder tumors. [2009.08]
The effect of high-dose vitamin A supplementation administered with BCG vaccine at birth may be modified by subsequent DTP vaccination. [2009.05.11]
[BCG versus photodynamic therapy (PDT) for nonmuscle invasive bladder cancer-a multicentre clinical phase III study] [2009.03]
Protection of free-living and captive possums against pulmonary challenge with Mycobacterium bovis following oral BCG vaccination. [2009.03]
Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer. [2009.03]
A randomized prospective study of intravesical prophylaxis in non-musle invasive bladder cancer at intermediate risk of recurrence: mitomycin chemotherapy vs BCG immunotherapy. [2008.12]
Efficacy of percutaneous versus intradermal BCG in the prevention of tuberculosis in South African infants: randomised trial. [2008.11.13]
Vaccination of cattle with Mycobacterium bovis BCG by a combination of systemic and oral routes. [2008.11]
Symptom and quality of life results of an international randomised phase III study of adjuvant vaccination with Bec2/BCG in responding patients with limited disease small-cell lung cancer. [2008.10]
Poor immunogenicity of BCG in helminth infected population is associated with increased in vitro TGF-beta production. [2008.07.23]
Can early single dose instillation of epirubicin improve bacillus Calmette-Guerin efficacy in patients with nonmuscle invasive high risk bladder cancer? Results from a prospective, randomized, double-blind controlled study. [2008.07]
Effect of 50,000 IU vitamin A given with BCG vaccine on mortality in infants in Guinea-Bissau: randomised placebo controlled trial. [2008.06.21]
The effect of intravesical instillation of antifibrinolytic agents on bacillus Calmette-Guerin treatment of superficial bladder cancer: a pilot study. [2008.04]
BCG revaccination does not protect against leprosy in the Brazilian Amazon: a cluster randomised trial. [2008.02.13]
[Immunotherapeutic efficacy of BCG vaccine in pulmonary tuberculosis and its preventive effect on multidrug-resistant tuberculosis] [2008.02]
Followup of patients with interstitial cystitis responsive to treatment with intravesical bacillus Calmette-Guerin or placebo. [2008.02]
Immunogenicity and safety of combined intradermal recombinant Hepatitis B with BCG vaccines at birth. [2008.01.30]
Persistence of the immune response induced by BCG vaccination. [2008.01.25]
Sex-differential effect on infant mortality of oral polio vaccine administered with BCG at birth in Guinea-Bissau. A natural experiment. [2008]
The safety and efficacy of different doses of bacillus Calmette Guerin in superficial bladder transitional cell carcinoma. [2007.12]
Evaluation of a novel immunomodulator composed of human chorionic gonadotropin and bacillus Calmette-Guerin for treatment of canine mast cell tumors in clinically affected dogs. [2007.11]
Effect of vitamin A supplementation with BCG vaccine at birth on vitamin A status at 6 wk and 4 mo of age. [2007.10]
[Effects of BCG-PSN injection on immune and lung function of asthmatic children complicated with allergic rhinitis] [2007.09]
Did patients with interstitial cystitis who failed to respond to initial treatment with bacillus Calmette-Guerin or placebo in a randomized clinical trial benefit from a second course of open label bacillus Calmette-Guerin? [2007.09]
Vaccination of cattle with Danish and Pasteur strains of Mycobacterium bovis BCG induce different levels of IFNgamma post-vaccination, but induce similar levels of protection against bovine tuberculosis. [2007.07.15]
[Acupoint-injection of BCG polysaccharide nuclear acid for treatment of condyloma acuminatum and its immunoregulatory action on the patient] [2007.06]
Well-designed clinical trials possibly related to BCG Vaccine (Bacillus Calmette-Guerin)
Do new TB vaccines have a place in the Expanded Program on Immunization? [2011.12]
Primary isoniazid prophylaxis against tuberculosis in HIV-exposed children. [2011.07.07]
Immunogenicity of the tuberculosis vaccine MVA85A is reduced by coadministration with EPI vaccines in a randomized controlled trial in Gambian infants. [2011.06.22]
Immunogenicity of a protective whole cell mycobacterial vaccine in HIV-infected adults: a phase III study in Tanzania. [2010.11.10]
Interferon gamma responses to mycobacterial antigens protect against subsequent HIV-associated tuberculosis. [2010.10.15]
The effect of high-dose vitamin A supplementation given with bacille Calmette-Guerin vaccine at birth on infant rotavirus infection and diarrhea: a randomized prospective study from Guinea-Bissau. [2010.09.01]
The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults. [2010.06.15]
Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naive human volunteers. [2010.04.30]
Gemcitabine versus bacille Calmette-Guerin after initial bacille Calmette-Guerin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial. [2010.04.15]
Prevention of tuberculosis in Bacille Calmette-Guerin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine. [2010.03.13]
Comparison between three adjuvants for a vaccine against canine leishmaniasis: In vitro evaluation of macrophage killing ability. [2010.03]
Does vitamin A supplementation interact with routine vaccinations? An analysis of the Ghana Vitamin A Supplementation Trial. [2009.09]
Lymphocyte proliferation to mycobacterial antigens is detectable across a spectrum of HIV-associated tuberculosis. [2009.02.23]
A new recombinant bacille Calmette-Guerin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers. [2008.11.15]
Early atopic disease and early childhood immunization--is there a link? [2008.11]
Thymus size at 6 months of age and subsequent child mortality. [2008.11]
No adverse events after simultaneous administration of 50 000 IU vitamin A and Bacille Calmette-Guerin vaccination to normal-birth-weight newborns in Guinea-Bissau. [2008.07]
[Comparison of the effectiveness between long-term instillation of mitomycin C and short-term prophylaxis with MMC or bacille Calmette-Guerin. Study of patients with non-muscle-invasive urothelial cancer of the urinary bladder] [2008.05]
Does photodynamic transurethral resection of bladder tumour improve the outcome of initial T1 high-grade bladder cancer? A long-term follow-up of a randomized study. [2008.03]
Potential of Mw as a prophylactic vaccine against pulmonary tuberculosis. [2008.02.26]
Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer. [2008.01.01]
Immunochemotherapy of persistent post-kala-azar dermal leishmaniasis: a novel approach to treatment. [2008.01]
Bacille-Calmette-Guerin vaccination and the development of allergic disease in children: a randomized, prospective, single-blind study. [2008.01]
Effect of high-dose vitamin A supplementation on the immune response to Bacille Calmette-Guerin vaccine. [2007.10]
Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III. [2007.09]
Other research related to BCG Vaccine (Bacillus Calmette-Guerin)
Effectiveness and cost-effectiveness of first BCG vaccination against tuberculosis in school-age children without previous tuberculin test (BCG-REVAC trial): a cluster-randomised trial. [2011.11.07]
The Influence of BCG Vaccine Strain on the Immune Response against Tuberculosis: a Randomised Trial. [2011.11.03]
Factors affecting response to bacillus Calmette-Guerin plus interferon for urothelial carcinoma in situ. [2011.09]
Inhibition of allergen-induced airway remodeling by neonatal bacillus Calmette-Guerin vaccination is associated with interferon-gamma-producing T cells but not regulatory T cells in mice. [2011.08]
The efficacy of Bacillus Calmette-Guerin vaccinations for the prevention of acute upper respiratory tract infection in the elderly. [2011.07]
Disseminated BCG as a unique feature of an infant with severe combined immunodeficiency. [2011.05]
The Effect of 50 000 IU Vitamin A with BCG Vaccine at Birth on Growth in the First Year of Life. [2011]
Oral polio vaccine influences the immune response to BCG vaccination. A natural
experiment. [2010]
Effect of revaccination with BCG in early childhood on mortality: randomised
trial in Guinea-Bissau. [2010]
Vitamin A supplementation and BCG vaccination at birth in low birthweight
neonates: two by two factorial randomised controlled trial. [2010]
Other possibly related research studies
Consensus Statement on Diagnostic End Points for Infant Tuberculosis Vaccine Trials. [2011.12.05]
Bacille Calmette-Guerin lymphadenitis and recurrent oral candidiasis in an infant with a new mutation leading to interleukin-12 receptor beta-1 deficiency. [2011]
Tuberculosis vaccines: progress and challenges. [2011.10]
Fact and fiction in tuberculosis vaccine research: 10 years later. [2011.08]
Disseminated tuberculosis in human immunodeficiency virus infection: ineffective immunity, polyclonal disease and high mortality. [2011.08]
Interventions for preventing infection in nephrotic syndrome. [2012]
Intravesical gemcitabine for non-muscle invasive bladder cancer. [2012]
Intravesical therapy for superficial bladder cancer: a systematic review of
randomised trials and meta-analyses. [2010]
Comparison between three adjuvants for a vaccine against canine leishmaniasis: In
vitro evaluation of macrophage killing ability. [2010]
|
